Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...

Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years ...

Patients with type 2 diabetes who used the Omnipod 5 had lower A1C after 8 weeks. Those who had been using multiple daily injections achieved the greatest benefits in reduced hypoglycemia and ...

The FDA has cleared the Omnipod 5 Automated Insulin Delivery System for individuals aged 6 years and older with type 1 diabetes.

A US-listed medical device maker worth about $25 billion plans to expand into the Middle East next year, entering a region where diabetes rates are among the highest globally. Insulet specialises in ...

Omnipod offers products to manage and monitor your diabetes. Here’s everything you need to know, including features and pricing, about the Omnipod DASH and the Omnipod 5.

Researchers discovered that the Omnipod System was effective in controlling blood glucose levels in patients who switched from multiple daily injections (MDI) or from traditional tubed insulin pumps.

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Omnipod 5 is now commercially available in Australia with Dexcom G6 and G7 compatibility, with plans underway to soon add Abbott’s FreeStyle Libre ® 2 Plus.

The diabetes devicemaker has earned FDA clearance for the iPhone version of an app allowing users to control their Omnipod 5 insulin pumps from their own smartphones.

Even without the rollout of the latest model of its tubeless insulin pump system—the Omnipod 5, which was originally poised to receive FDA clearance early last year but didn’t sec | Even ...